Teva, Lilly and Amgen join battle for new $8bn migraine prevention market
This article was originally published in Scrip
New biologicals targeting the CGRP pathway could prove to be the biggest thing to hit the migraine market since the triptans in the 1990s, mid-stage data presented at the recent American Headache Society meeting in Washington suggest.
You may also be interested in...
Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.
Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.